Royalty Financing Dealmaking in Biopharma Industry Discussed in New Research Report Available at MarketPublishers.com
New research report “Royalty Financing Terms and Agreements in Pharma, Biotech and Diagnostics” elaborated by CurrentPartnering has been recently published by Market Publishers Ltd.
London, UK (PRWEB) September 03, 2012
Contract documents provide the answers to numerous questions about a prospective partner´s flexibility on a wide range of important issues, many of which will have a significant impact on each party´s ability to derive value from the deal.
What are the precise rights granted? What is actually granted by the agreement to the acquiring company? What is the payment structure for the deal? How are sales and payments audited? How do the parties work together during transition? What is the deal term? How are the key terms of the agreement defined? How are IPRs handled and owned? Who is responsible for commercialization? Who is responsible for development, supply, and manufacture? How is confidentiality and publication managed? How are disputes to be resolved? Under what conditions can the deal be terminated?
All these key questions and a lot more are discussed within the new research report “Royalty Financing Terms and Agreements in Pharma, Biotech and Diagnostics” elaborated by CurrentPartnering and recently published by Market Publishers Ltd.
Title: Royalty Financing Terms and Agreements in Pharma, Biotech and Diagnostics
Published: May, 2012
Price: US$ 2,695.00 http://marketpublishers.com/report/medicine_pharmaceuticals_biotechnology/healthcare_equipment_services/royalty_financing_agreements_in_pharma_biotech_n_diagnostics.html
The research report is aimed to provide an in-depth understanding and unprecedented access to the royalty financing agreements entered into by the top biopharma companies worldwide, besides explaining how and why these companies enter these deals.
- trends in royalty financing dealmaking in the biopharma industry since 2007;
- analysis of royalty financing deal structure;
- case studies of real-life royalty financing deals;
- comprehensive listing of royalty financing deals since 2007;
- access to royalty financing contract documents;
- leading royalty financing deals by value since 2007;
- most active royalty financing dealmakers since 2007;
- major royalty financing partnering resources.
Available contracts are listed by: company A-Z, headline value and therapeutic area.
Chapter 1 – Introduction
Chapter 2 – Trends in Royalty Financing Dealmaking
2.2. Difference between royalty and revenue financing
2.3. Trends in royalty financing deals since 2007
2.4. Reasons for entering into royalty financing partnering deals
2.5 The emergence of royalty asset purchase deals
2.4.1. Primary players in royalty asset purchase deals
2.4.2. Recent royalty asset purchase deals
2.4.3. The role of bigpharma in royalty buyback
2.4.4. The future of royalty asset purchase deals
Chapter 3 – Overview of Royalty Financing Structure
3.2. Anatomy of a royalty asset purchase agreement
3.3. Example royalty financing agreements
3.3.1. Case study 1: Emory University – Gilead Sciences – Royalty Pharma – July 2005
3.3.2. Case study 2: Enzon – Drug Royalty – August 2007
3.3.3. Case study 3: Royalty asset: DRI Capital – NPS Pharmaceuticals – July 2007
3.3.4. Case study 4: Royalty asset: TPG – CV Therapeutics – April 2008
Chapter 4 – Leading Royalty Financing Deals
4.2. Top royalty financing deals by value
4.3. Top revenue financing deals by value
4.4. Most active royalty financing dealmakers
Chapter 5 – Royalty Financing Contract Documents 2007-2012
5.2. Company A-Z
Chapter 6 – Royalty Financing Agreement Directory 2007-2012
6.2. Company A-Z
6.3. By therapy area
Appendix 1 – Royalty financing references
Appendix 2 – Resources
Appendix 3 – Deal type definitions
Appendix 4 – Example royalty financing contract document
About Wildwood Ventures
Recent report titles from CurrentPartnering
Table of Figures
Figure 1: Definition of royalty assets
Figure 2: Trends in royalty financing deal announcements, 2007-2012
Figure 3: Trends in revenue financing or ℠synthetic royalty´ deal announcements, 2007-2012
Figure 4: Leading royalty asset investors
Figure 5: Recent royalty asset purchase agreements
Figure 6: Components of the royalty asset purchase deal structure
Figure 7: Top royalty financing deals by value since 2007
Figure 8: Top revenue financing deals by value since 2007
Figure 9: Most active royalty financing dealmakers 2007-2012
Figure 10: Online partnering resources
Figure 11: Deal type definitions
Figure 12: Royalty financing agreement for Qutenza – April 2010
More new research reports by the publisher can be found at CurrentPartnering page.
For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2012/9/prweb9862929.htm